Zhang Tianyi, Zhao Shilei, Gu Chundong
Department of Thoracic Surgery, Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Dalian Medical University, Dalian, 116011, China.
J Mol Histol. 2025 Jan 30;56(2):77. doi: 10.1007/s10735-025-10360-3.
Malignant tumors are among the major diseases threatening human survival in the world, and advancements in medical technology have led to a steady increase in their detection rates worldwide. Despite unique clinical presentations across the spectrum of malignancies, treatment modalities generally adhere to common strategies, encompassing primarily surgical intervention, radiation therapy, chemotherapy, and targeted treatments. Uncovering the genetic elements contributing to cancer cell proliferation, metastasis, and drug resistance remains a pivotal pursuit in the development of novel targeted therapeutics. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A/PGC-1α) is a transcriptional coactivator that influences most cellular metabolic pathways. Its aberrant expression is associated with numerous chronic diseases, including diabetes, heart failure, neurodegenerative disorders, and cancer development. This study primarily discusses the structure, physiological functions, regulatory mechanisms, and research advancement concerning the role of PGC-1α in the proliferation and metastasis of malignant tumors. Targeting PGC-1α and its related regulatory pathways for therapeutic interventions holds promise in facilitating precise and individualized oncological treatments. This approach is expected to counteract drug resistance in patients with cancer and offer a novel direction for the treatment of malignant tumors.
恶性肿瘤是威胁全球人类生存的主要疾病之一,医学技术的进步使得全球范围内其检出率稳步上升。尽管恶性肿瘤在临床表现上具有独特性,但治疗方式通常遵循常见策略,主要包括手术干预、放射治疗、化疗和靶向治疗。揭示导致癌细胞增殖、转移和耐药的基因因素仍然是新型靶向治疗药物研发的关键追求。过氧化物酶体增殖物激活受体γ共激活因子1α(PPARGC1A/PGC-1α)是一种转录共激活因子,影响大多数细胞代谢途径。其异常表达与多种慢性疾病相关,包括糖尿病、心力衰竭、神经退行性疾病和癌症发展。本研究主要讨论PGC-1α在恶性肿瘤增殖和转移中的作用的结构、生理功能、调控机制和研究进展。针对PGC-1α及其相关调控途径进行治疗干预有望促进精准和个体化的肿瘤治疗。这种方法有望对抗癌症患者的耐药性,并为恶性肿瘤的治疗提供新的方向。